Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Silent NK/T Cell Reactions Against Dasatinib during Sustained Deep Molecular Response before Discontinuation Are Associated with Longer Treatment-Free Remission: A Multicenter, Single-Arm, Phase 2 Study

Takashi Kumagai, MD PhD, Chiaki Nakaseko, MD PhD, Kaichi Nishiwaki, MD, Chikashi Yoshida, MD PhD, Kazuteru Ohashi, MD PhD, Naoki Takezako, MD PhD, Hina Takano, MD PhD, Yasuji Kouzai, MD PhD, Tadashi Murase, MD PhD, Kosei Matsue, MD PhD, Satoshi Morita, PhD Prof., Junichi Sakamoto,, MD PhD, Hisashi Wakita, MD PhD, Hisashi Sakamaki, MD PhD, Koiti Inokuchi, MD PhD Prof.

Blood (2019) 134 (Supplement_1): 4154.

https://doi.org/10.1182/blood-2019-130504

Published: 2019

Journal Articles

Association of Peripheral Regulatory T Cells with Achievement of Deep Molecular Response in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Treated with Dasatinib - the Final Results of D-First Study

Chikashi Yoshida, MD PhD, Noriyoshi Iriyama, MDPhD, Yuho Najima, Shin Fujisawa, MD PhD, Hisashi Wakita, MD PhD, Shigeru Chiba, MD, PhD, Shinichiro Okamoto, MD PhD, Kimihiro Kawakami, MDPhD, Naoki Takezako, MD PhD, Takashi Kumagai, MD PhD, Kazuma Ohyashiki, MD PhD, Jun Taguchi, MD PhD, Shingo Yano, MD PhD, Tadahiko Igarashi, MD, Yasuji Kouzai, MD PhD, Satoshi Morita, PhD Prof, Junichi Sakamoto, MD PhD, Hisashi Sakamaki, MD PhD, Koiti Inokuchi, MD PhD Prof

Blood (2016) 128 (22): 1916.

https://doi.org/10.1182/blood.V128.22.1916.1916

Published: 2016

Journal Articles

Discontinuation of Dasatinib after Deep Molecular Response for over 2 Years in Patients with Chronic Myelogenous Leukemia and the Unique Profiles of Lymphocyte Subsets for Successful Discontinuation: A Prospective, Multicenter Japanese Trial (D-STOP Trial)

Takashi Kumagai, MD PhD, Chiaki Nakaseko, MD, Kaichi Nishiwaki, MD PhD, Chikashi Yoshida, MD PhD, Kazuteru Ohashi, Naoki Takezako, MD PhD, Hina Takano, MD PhD, Yasuji Kouzai, MD PhD, Tadashi Murase, MD PhD, Kosei Matsue, MD PhD, Satoshi Morita, PhD Prof, Junichi Sakamoto, MD PhD, Hisashi Wakita, MD PhD, Hisashi Sakamaki, MD PhD, Koiti Inokuchi, MD PhD Prof

Blood (2016) 128 (22): 791.

https://doi.org/10.1182/blood.V128.22.791.791

Published: 2016

Journal Articles

Efficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy

Yasuyuki Arai, June Takeda, Kazunari Aoki, Tadakazu Kondo, Satoshi Takahashi, Yasushi Onishi, Yukiyasu Ozawa, Nobuyuki Aotsuka, Yasuji Kouzai, Hirohisa Nakamae, Shuichi Ota, Chiaki Nakaseko, Hiroki Yamaguchi, Koji Kato, Yoshiko Atsuta, Akiyoshi Takami

Blood (2015) 126 (3): 415–422.

https://doi.org/10.1182/blood-2015-04-642652

Published: 2015

Includes: Supplemental data

Journal Articles

The Incidence of Pleural Effusion on Dasatinib Treatment Is Associated with CD56 Positive Cell Values One Month after Commencing Dasatinib and Achievement of an Early Molecular Response in Newly Diagnosed Chronic Myeloid Leukemia Patients: Results of a D-First Study

Noriyoshi Iriyama, Shin Fujisawa, MD, Maki Hagihara, MDPhD, Chikashi Yoshida, MD PhD, Hisashi Wakita, MD PhD, Shigeru Chiba, MD PhD, Shinichiro Okamoto, MD PhD, Kawakami Kimihiro, Naoki Takezako, MD PhD, Takashi Kumagai, MD PhD, Koiti Inokuchi, MD PhD, Kazuma Ohyashiki, Jun Taguchi, MD PhD, Shingo Yano, Tadahiko Igarashi, MD PhD, Yasuji Kouzai, MD PhD, Satoshi Morita, PhD, Junichi Sakamoto, MDPhD, Hisashi Sakamaki, MDPhD

Blood (2014) 124 (21): 3142.

https://doi.org/10.1182/blood.V124.21.3142.3142

Published: 2014

Journal Articles

A Shorter Halving Time for BCR-ABL transcript Reduction Is a Novel Predictor of Molecular Response Achievement in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Patients Treated with Dasatinib: Results of D-First Study

Maki Hagihara, MDPhD, Noriyoshi Iriyama, MDPhD, Chikashi Yoshida, MD PhD, Shin Fujisawa, MD, Hisashi Wakita, MD PhD, Shigeru Chiba, MD PhD, Naoki Takezako, MD PhD, Kimihiro Kawakami, MD PhD, Shinichiro Okamoto, MD PhD, Koiti Inokuchi, MD PhD, Kazuma Ohyashiki, Takashi Kumagai, MD PhD, Jun Taguchi, MD PhD, Shingo Yano, Tadahiko Igarashi, MD PhD, Yasuji Kouzai, MD PhD, Junichi Sakamoto, MDPhD, Satoshi Morita, PhD, Hisashi Sakamaki, MDPhD

Blood (2014) 124 (21): 1795.

https://doi.org/10.1182/blood.V124.21.1795.1795

Published: 2014

Journal Articles

Dasatinib Induces a Higher Molecular Response in Japanese Patients with Chronic Myeloid Leukemia After Imatinib Failure Than in Western Populations: Kanto CML Study

Yoshihiro Hatta, MD, PhD, Koiti Inokuchi, MD, PhD, Takashi Kumagai, MD, Kazuteru Ohashi, MD, Atsushi Shinagawa, MD, Jin Takeuchi, MD, Shinichiro Okamoto, MD, PhD, Hisashi Wakita, MD, Yasuji Kouzai, MD, Yukari Shirasugi, MD, Chikashi Yoshida, MD, Koji Oba, MD, Junichi Sakamoto, MD, Hisashi Sakamaki, MD

Blood (2011) 118 (21): 4448.

https://doi.org/10.1182/blood.V118.21.4448.4448

Published: 2011

NARROW

Silent NK/T Cell Reactions Against Dasatinib during Sustained Deep Molecular Response before Discontinuation Are Associated with Longer Treatment-Free Remission: A Multicenter, Single-Arm, Phase 2 Study

Association of Peripheral Regulatory T Cells with Achievement of Deep Molecular Response in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Treated with Dasatinib - the Final Results of D-First Study

Discontinuation of Dasatinib after Deep Molecular Response for over 2 Years in Patients with Chronic Myelogenous Leukemia and the Unique Profiles of Lymphocyte Subsets for Successful Discontinuation: A Prospective, Multicenter Japanese Trial (D-STOP Trial)

Efficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy

The Incidence of Pleural Effusion on Dasatinib Treatment Is Associated with CD56 Positive Cell Values One Month after Commencing Dasatinib and Achievement of an Early Molecular Response in Newly Diagnosed Chronic Myeloid Leukemia Patients: Results of a D-First Study

A Shorter Halving Time for BCR-ABL transcript Reduction Is a Novel Predictor of Molecular Response Achievement in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Patients Treated with Dasatinib: Results of D-First Study

Dasatinib Induces a Higher Molecular Response in Japanese Patients with Chronic Myeloid Leukemia After Imatinib Failure Than in Western Populations: Kanto CML Study

Email alerts

ASH Publications

American Society of Hematology

Silent NK/T Cell Reactions Against Dasatinib during Sustained Deep Molecular Response before Discontinuation Are Associated with Longer Treatment-Free Remission: A Multicenter, Single-Arm, Phase 2 Study

Association of Peripheral Regulatory T Cells with Achievement of Deep Molecular Response in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Treated with Dasatinib - the Final Results of D-First Study

Discontinuation of Dasatinib after Deep Molecular Response for over 2 Years in Patients with Chronic Myelogenous Leukemia and the Unique Profiles of Lymphocyte Subsets for Successful Discontinuation: A Prospective, Multicenter Japanese Trial (D-STOP Trial)

Efficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy

The Incidence of Pleural Effusion on Dasatinib Treatment Is Associated with CD56 Positive Cell Values One Month after Commencing Dasatinib and Achievement of an Early Molecular Response in Newly Diagnosed Chronic Myeloid Leukemia Patients: Results of a D-First Study

A Shorter Halving Time for BCR-ABL transcript Reduction Is a Novel Predictor of Molecular Response Achievement in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Patients Treated with Dasatinib: Results of D-First Study

Dasatinib Induces a Higher Molecular Response in Japanese Patients with Chronic Myeloid Leukemia After Imatinib Failure Than in Western Populations: Kanto CML Study

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only